Jacobs Levy Equity Management Inc. Purchases Shares of 30,346 Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Jacobs Levy Equity Management Inc. purchased a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 30,346 shares of the company’s stock, valued at approximately $274,000. Jacobs Levy Equity Management Inc. owned 0.09% of Lexeo Therapeutics as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of LXEO. Vanguard Group Inc. raised its holdings in Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after acquiring an additional 65,573 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Lexeo Therapeutics by 12.3% during the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after purchasing an additional 3,483 shares during the period. Rhumbline Advisers increased its holdings in shares of Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after purchasing an additional 3,627 shares during the period. Values First Advisors Inc. bought a new position in shares of Lexeo Therapeutics during the third quarter worth approximately $67,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Lexeo Therapeutics by 107.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after purchasing an additional 33,013 shares during the period. 60.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the sale, the chief executive officer now owns 120,695 shares in the company, valued at $977,629.50. This trade represents a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 4.50% of the company’s stock.

Lexeo Therapeutics Stock Performance

NASDAQ LXEO opened at $8.36 on Wednesday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $276.47 million and a price-to-earnings ratio of -2.65. The firm’s 50 day simple moving average is $8.20 and its 200 day simple moving average is $11.47. Lexeo Therapeutics, Inc. has a 1 year low of $5.77 and a 1 year high of $22.33.

Wall Street Analyst Weigh In

Several brokerages have recently commented on LXEO. Leerink Partners lowered their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. HC Wainwright raised their target price on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Chardan Capital raised their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Lexeo Therapeutics has a consensus rating of “Buy” and an average price target of $23.80.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.